Ju Fu Tang Biotech Affirms Stable Capital Base in April 2026; Maintains Public-Float Compliance

Bulletin Express
05/05

Ju Fu Tang Biotech Holdings Co., Ltd (Ju Fu Tang Biotech) has filed its monthly return for the period ended 30 April 2026 with Hong Kong Exchanges and Clearing Ltd., indicating no change in share capital structure during the month.

Authorised and Issued Capital • Authorised share capital remained at 500.00 million ordinary shares with a par value of HKD 0.16 each, equivalent to HKD 80.00 million. • Issued share capital was unchanged at 301.86 million ordinary shares. No treasury shares were held or cancelled.

Public-Float Status The company confirmed that it continued to meet the minimum 25% public-float requirement stipulated under GEM Rule 17.37B as at 30 April 2026.

Share Option Schemes • Scheme granted 12 Jul 2021 (exercise price: HKD 0.315; expiry: 11 Jul 2026): 10.70 million options outstanding. • Scheme granted 18 Mar 2022 (exercise price: HKD 0.163; expiry: 17 Mar 2027): 9.14 million options outstanding. No options were exercised or cancelled during the month, leaving 19.84 million options outstanding and an equivalent number of shares available for potential future issuance.

Other Equity Instruments The issuer reported no warrants, convertible securities, other share-issuance agreements, or treasury-share movements in April.

Compliance Confirmation Corporate secretary Tam Mei Chu confirmed that all necessary authorisations and regulatory requirements were met for the period under review.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10